HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

HealthCo Healthcare and Wellness REIT Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $357.61 million
P/E Ratio 67.62
Dividend Yield 2.98%
Shares Outstanding 550.18 million
Earnings per share -0.160
Dividend per share 0.08
Year To Date Return -2.76%
Earnings Yield 1.48%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

HealthCo Healthcare and Wellness REIT (ASX: HCW)
Latest News

man looking through window at sky scraper buildings
Broker Notes

This is the latest ASX 200 sector to be hit by downgrades

It seems there's no safe place to hide from the current volatility.

Read more »

Four businessmen pull martial arts stances as they get into a defensive position.
Investing Strategies

4 'defensive growth' ASX shares to buy in turbulent times: Wilsons

High inflation, rising interest rates and a war in Europe. The only certainty is more uncertainty.

Read more »

Happy child jumping for joy.
Small Cap Shares

5 profitable small-cap ASX shares to buy right now: Wilsons

With volatility all around the world, experts warn investors to stick with profitability. Here are some smaller businesses that are…

Read more »

red pen and sheet of paper with A plus written on it
Broker Notes

Top broker picks 6 ASX 200 shares with earnings surprise potential

A leading broker picks its top half dozen this reporting season.

Read more »

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Share Market News

2 ASX shares that top analysts are loving right now

Some of the best analysts have named some ASX shares to buy.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Share Market News

Goldman Sachs just added this ASX healthcare share to its conviction buy list

This healthcare share could be a strong buy..

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
REITs

The HCW (ASX:HCW) share price has gained 15% since the REIT's IPO

Here's how the healthcare-focused REIT has performed on the ASX so far .

Read more »

Motley Fool Chief Investment Officer Scott Phillips on nine news
Motley Fool Media

Fortescue's big fall, job ad numbers disappoint and rates in focus. Scott Phillips on Nine's Late News

Fortescue shareholders, including Twiggy Forrest, are to enjoy a massive payday which explained the fall in the Fortescue share price…

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
30 Dec 2024 $0.0210 0.00% Final 26 Feb 2025
27 Sep 2024 $0.0210 0.00% Interim 22 Nov 2024
27 Jun 2024 $0.0200 0.00% Final 22 Aug 2024
27 Mar 2024 $0.0200 0.00% Interim 22 May 2024
28 Dec 2023 $0.0200 0.00% Interim 21 Feb 2024
28 Sep 2023 $0.0200 0.00% Interim 29 Nov 2023
29 Jun 2023 $0.0200 0.00% Final 30 Aug 2023
01 May 2023 $0.0188 0.00% Interim 23 Jun 2023
29 Dec 2022 $0.0188 0.00% Interim 24 Feb 2023
29 Sep 2022 $0.0188 0.00% Interim 25 Nov 2022
29 Jun 2022 $0.0225 0.00% Final 22 Aug 2022
30 Mar 2022 $0.0225 0.00% Interim 20 May 2022
30 Dec 2021 $0.0300 0.00% Interim 25 Feb 2022

HCW ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About HealthCo Healthcare and Wellness REIT

HealthCo Healthcare and Wellness REIT are owning and managing a portfolio of commercial health and wellness real estate assets. It invests in high conviction and scalable real asset strategies on behalf of individuals, large institutions and super funds.

HCW Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
06 Mar 2026 $0.65 $0.00 0.00% 608,820 $0.65 $0.67 $0.64
05 Mar 2026 $0.65 $-0.02 -3.01% 1,856,379 $0.67 $0.67 $0.65
04 Mar 2026 $0.67 $-0.01 -1.48% 603,528 $0.67 $0.68 $0.66
03 Mar 2026 $0.68 $-0.02 -2.88% 589,034 $0.70 $0.70 $0.67
02 Mar 2026 $0.70 $-0.03 -4.17% 647,956 $0.71 $0.71 $0.69
27 Feb 2026 $0.72 $0.01 1.41% 977,122 $0.70 $0.73 $0.70
26 Feb 2026 $0.71 $0.01 1.43% 1,218,830 $0.71 $0.74 $0.71
25 Feb 2026 $0.70 $0.01 1.45% 877,681 $0.71 $0.71 $0.69
24 Feb 2026 $0.69 $0.01 1.47% 1,345,119 $0.68 $0.70 $0.67
23 Feb 2026 $0.68 $-0.01 -1.44% 757,903 $0.70 $0.70 $0.68
20 Feb 2026 $0.70 $0.00 0.00% 892,979 $0.70 $0.70 $0.68
19 Feb 2026 $0.70 $-0.02 -2.82% 561,926 $0.71 $0.71 $0.69
18 Feb 2026 $0.71 $0.01 1.43% 1,540,780 $0.69 $0.72 $0.69
17 Feb 2026 $0.70 $0.03 4.48% 1,379,012 $0.69 $0.71 $0.67
16 Feb 2026 $0.67 $0.01 1.52% 991,056 $0.66 $0.68 $0.65
13 Feb 2026 $0.66 $-0.01 -1.50% 833,881 $0.67 $0.67 $0.65
12 Feb 2026 $0.67 $-0.01 -1.49% 1,036,065 $0.67 $0.67 $0.66
11 Feb 2026 $0.67 $-0.02 -2.92% 5,611,824 $0.70 $0.70 $0.65
10 Feb 2026 $0.69 $0.00 0.00% 1,742,489 $0.70 $0.70 $0.68
09 Feb 2026 $0.69 $-0.02 -2.84% 1,113,044 $0.72 $0.72 $0.69
06 Feb 2026 $0.71 $-0.01 -1.41% 712,774 $0.72 $0.73 $0.70
05 Feb 2026 $0.71 $0.00 0.00% 1,720,224 $0.73 $0.73 $0.70
04 Feb 2026 $0.71 $-0.02 -2.74% 2,654,826 $0.73 $0.73 $0.71

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Aug 2025 Kelly O'Dwyer Buy 21,658 $16,893
As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.
27 Aug 2025 Joseph Carrozzi Buy 21,047 $16,416
As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.
27 Aug 2025 Natalie Meyenn Buy 25,565 $19,940
As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Christopher Graham Roberts Non-Executive Director Aug 2021
Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010. He was Chair of The Engineering and Design Institute London (TEDI London) (resigned on 19 May 2023).
Ms Stephanie Mei-Nga Lai Non-Executive Director Aug 2021
Ms Lai has over 25 years of experience and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of the Risk Committee.
Mr David Anthony Di Pilla Non-Executive Director Jul 2021
Mr Pilla led the team that founded the consortium which led to the ultimate establishment of HMC Capital Limited in 2016. Since this time, the HMC Group has grown from its initial Masters portfolio to today being an alternative asset manager with assets under management of approximately $18.5 billion. David has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20-year investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's transactions across corporate mergers and acquisitions, and equity and debt capital markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
Hon Kelly Megan O'Dwyer Non-Executive Director Aug 2021
Hon O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking. Kelly is also a Non-Executive Director of Barrenjoey Capital Partners Group Holdings Pty Ltd and the National Reconstruction Fund Corporation.
Mr Joseph Carrozzi Non-Executive ChairmanNon-Executive Director Aug 2021
Mr Carrozzi has over 30 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the President of Business NSW, the Chair of the Centenary Institute for Medical Research and AKG Group (a private employment services business), as well as a board member of Football Australia. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport and a former board member of Western Sydney University and the National Intermodal Corporation. He is on the UNSW Dean's Advisory Council for the Faculty of Medicine. He is member of the Risk Committee.
Ms Natalie Jane Meyenn Non-Executive Director Aug 2021
Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity, and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non profits including New Energy Nexus and Yielco Investments. She worked in investment banking (mergers and acquisitions, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is member of the Risk Committee.
Mr Andrew Selim Company SecretaryGeneral Counsel
-
Andrew Selim Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Home Consortium Developments Limited 89,871,409 16.34%
J P Morgan Nominees Australia Pty Limited 86,335,952 15.69%
HSBC Custody Nominees (Australia) Limited 62,321,284 11.33%
Home Consortium Limited 35,034,393 6.37%
Citicorp Nominees Pty Limited 34,995,999 6.36%
BNP Paribas Noms Pty Ltd 22,633,093 4.11%
BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) 7,369,385 1.34%
Netwealth Investments Limited (Wrap Services A/C) 6,901,705 1.25%
National Nominees Limited 5,866,514 1.07%
Buttonwood Nominees Pty Ltd 5,734,186 1.04%
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,547,184 0.83%
Netwealth Investments Limited (Super Services a/c) 2,527,985 0.46%
Mr David Edward Ogden and Mrs Amanday Jay Ogden (D & A Ogden Family A/C) 2,403,833 0.44%
Ubs Nominees Pty Ltd 2,290,401 0.42%
HSBC Custody Nominees (Australia) Limited A/C 2 2,111,567 0.38%
BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 1,806,826 0.33%
Aldaoud Pty Ltd (Aldaoud Family A/C) 1,500,000 0.27%
Neweconomy Com AU Nominees Pty Limited (900 Account) 1,497,949 0.27%
Glengallan Investments Pty Ltd 1,188,249 0.22%
Premium Capital (Aust) Pty Ltd 1,040,020 0.19%

Profile

since

Note